-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ma1XQH+/e+tSjEc8oOTflFXpruEG/Jdd6qWISWtZeR7cheJqQAlfm5Ywvaua/VA2
 kvLX9oke0Ul8kidCDGGzzQ==

<SEC-DOCUMENT>0001143313-09-000049.txt : 20090407
<SEC-HEADER>0001143313-09-000049.hdr.sgml : 20090407
<ACCEPTANCE-DATETIME>20090407154957
ACCESSION NUMBER:		0001143313-09-000049
CONFORMED SUBMISSION TYPE:	25-NSE
CONFIRMING COPY:	
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090407
DATE AS OF CHANGE:		20090407

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEPHROS INC
		CENTRAL INDEX KEY:			0001196298
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133971809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		25-NSE
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32288

	BUSINESS ADDRESS:	
		STREET 1:		41 GRAND AVENUE
		CITY:			RIVER EDGE,
		STATE:			NJ
		ZIP:			07661
		BUSINESS PHONE:		201.343.5202

	MAIL ADDRESS:	
		STREET 1:		41 GRAND AVENUE
		CITY:			RIVER EDGE,
		STATE:			NJ
		ZIP:			07661

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NYSE Amex
		CENTRAL INDEX KEY:			0001143313
		IRS NUMBER:				522127241

	FILING VALUES:
		FORM TYPE:		25-NSE

	BUSINESS ADDRESS:	
		STREET 1:		20 BROAD ST, 17TH FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
		BUSINESS PHONE:		212-656-5542

	MAIL ADDRESS:	
		STREET 1:		20 BROAD ST, 17TH FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NYSE Alternext US LLC
		DATE OF NAME CHANGE:	20081009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN STOCK EXCHANGE LLC
		DATE OF NAME CHANGE:	20010620
</SEC-HEADER>
<DOCUMENT>
<TYPE>25-NSE
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001143313</cik>
        <entityName>NYSE Amex</entityName>
    </exchange>

    <issuer>
        <cik>0001196298</cik>
        <entityName>NEPHROS INC</entityName>
        <fileNumber>001-32288</fileNumber>
        <address>
            <street1>41 Grand Avenue</street1>
            <street2></street2>
            <city>River Edge</city>
            <stateOrCountryCode>NJ</stateOrCountryCode>
            <stateOrCountry>NEW JERSEY</stateOrCountry>
            <zipCode>07661</zipCode>
        </address>
        <telephoneNumber>201-343-5202</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Common Stock, $0.001 Par Value</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(b)</ruleProvision>

    <signatureData>
        <signatureName>Janice O'Neill</signatureName>
        <signatureTitle>Senior Vice President - Corporate Compliance</signatureTitle>
        <signatureDate>2009-04-07</signatureDate>
    </signatureData>
</notificationOfRemoval>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.25
<SEQUENCE>2
<FILENAME>nep20090407.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>AMERICAN STOCK EXCHANGE LLC</TITLE>
<META NAME="author" CONTENT="mmcsweeny">
<META NAME="date" CONTENT="01/30/2009">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:511.2pt"><P style="line-height:14pt; margin:0pt; padding-right:-13.5pt; font-size:12pt" align=center><B><U>NYSE Amex LLC</U></B></P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; padding-right:-13.5pt; font-size:11pt" align=center>DETERMINATION AND NOTIFICATION OF REMOVAL FROM LISTING</P>
<P style="line-height:13pt; margin:0pt; padding-right:-13.5pt; font-size:11pt" align=center>AND/OR REGISTRATION UNDER SECTION 12(b) OF THE</P>
<P style="line-height:13pt; margin:0pt; padding-right:-13.5pt; font-size:11pt" align=center>SECURITIES EXCHANGE ACT OF 1934</P>
<P style="line-height:13pt; margin:0pt; padding-right:-13.5pt; font-size:11pt" align=center>Attachment to Form 25</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; padding-right:-13.5pt; font-size:11pt" align=center><U>April 7, 2009</U></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>NYSE Amex LLC (the &#147;Exchange&#148;), pursuant to Section 12(d) of the Securities Exchange Act of 1934 and Rule 12d2-2(b) promulgated thereunder by the Securities and Exchange Commission (the &#147;SEC&#148; or the &#147;Commission&#148;), has determined to strike from listing and registration on the Exchange, the following:</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center><B>Nephros, Inc.</B></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center><U>Common Stock, $0.001 Par Value</U></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center><U>Commission File Number &#150; 001-32288</U></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>1.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>The standards of the Exchange provide, among other things, that consideration may be given to the removal of a security when: (i) the financial condition and/or operating results of the issuer appear to be unsatisfactory; (ii) the issuer has failed to comply with its listing agreements with the Exchange; or (iii) any other event shall occur or any condition shall exist which makes further dealings on the Exchange unwarranted.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>In applying these standards, the Exchange gives consideration to delisting the securities of a company that is not in compliance with or is subject to: &nbsp;&nbsp;</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:56.15pt; text-indent:-18.75pt; font-size:11pt" align=justify>(a)</P>
<P style="line-height:13pt; margin:0pt; padding-left:56.15pt; font-size:11pt" align=justify>Section 1003(a)(ii) of the Company Guide which requires a company to maintain at least $4 million in stockholders&#146; equity if the company has reported losses from continuing operations and/or net losses in three out of its four most recent fiscal years; </P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:56.15pt; text-indent:-18.75pt; font-size:11pt" align=justify>(b)</P>
<P style="line-height:13pt; margin:0pt; padding-left:56.15pt; font-size:11pt" align=justify>Section 1003(a)(iii) of the Company Guide which requires a company to maintain at least $6 million in stockholders&#146; equity if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years; and</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:56.15pt; text-indent:-18.75pt; font-size:11pt" align=justify>(c)</P>
<P style="line-height:13pt; margin:0pt; padding-left:56.15pt; font-size:11pt" align=justify>Section 1003(f)(v) of the Company Guide which states that the Exchange will normally consider suspending dealings in, or removing from the list, a security selling for a substantial period of time at a low price per share.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>2.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>The Common Stock (the &#147;Common Stock&#148;) of Nephros, Inc. (the &#147;Company&#148; or &#147;Nephros&#148;) does not qualify for continued listing for the following reasons:</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>(a) &nbsp;The Company has incurred losses from continuing operations and net losses as follows:</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; font-size:11pt" align=justify><U>Years ended December 31,</U></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; text-indent:144pt; font-size:11pt" align=justify><U>Losses from Continuing Operations</U></P>
<P style="line-height:13pt; margin:0pt; padding-left:72pt; text-indent:324pt; font-size:11pt" align=justify><U>Net Loss</U></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:108pt; font-size:11pt" align=justify>2007</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:108pt; text-indent:144pt; font-size:11pt" align=justify>$7,479,000</P>
<P style="line-height:13pt; margin:0pt; padding-left:108pt; text-indent:288pt; font-size:11pt" align=justify>$26,356,000</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:108pt; font-size:11pt" align=justify>2006</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:108pt; text-indent:144pt; font-size:11pt" align=justify>$8,032,000</P>
<P style="line-height:13pt; margin:0pt; padding-left:108pt; text-indent:288pt; font-size:11pt" align=justify>$8,013,000</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; text-indent:36pt; font-size:11pt" align=justify>2005</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; text-indent:180pt; font-size:11pt" align=justify>$6,324,000</P>
<P style="line-height:13pt; margin:0pt; padding-left:72pt; text-indent:324pt; font-size:11pt" align=justify>$5,468,000</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; text-indent:36pt; font-size:11pt" align=justify>2004</P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:72pt; text-indent:180pt; font-size:11pt" align=justify>$7,646,000</P>
<P style="line-height:13pt; margin:0pt; padding-left:72pt; text-indent:324pt; font-size:11pt" align=justify>$7,596,000</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin:0pt; padding-left:36pt; font-size:11pt" align=justify>(b) &nbsp;At September 30, 2008, the Company reported stockholders&#146; equity of $3,406,000.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>3.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>In reviewing the eligibility of the Company&#146;s Common Stock for continued listing, the Exchange has complied with its standards and procedures as follows: </P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:54pt; text-indent:-18pt; font-size:11pt" align=justify>(a)</P>
<P style="line-height:normal; margin:0pt; padding-left:54pt; font-size:11pt" align=justify>On September 12, 2008, the Company was notified by the Exchange that following a review of its quarterly report on Form 10-Q for the period ended June 30, 2008, Nephros was not in compliance with Section 1003(a)(iii) of the Company Guide.<FONT FACE="CG Times">1</FONT> &nbsp;The Company was offered the opportunity to submit a plan of compliance to the Exchange detailing actions which it had taken, or intended to take, to regain compliance with the Exchange&#146;s continued listing standards by April 30, 2009 (the &#147;Plan&#148;).<FONT FACE="CG Times">2</FONT></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:54pt; text-indent:-18pt; font-size:11pt" align=justify>(b)</P>
<P style="line-height:13pt; margin:0pt; padding-left:54pt; font-size:11pt" align=justify>On October 13, 2008, Nephros submitted its Plan to the Exchange.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:54pt; text-indent:-18pt; font-size:11pt" align=justify>(c)</P>
<P style="line-height:13pt; margin:0pt; padding-left:54pt; font-size:11pt" align=justify>After reviewing the Plan, Staff determined that the Plan did not present a reasonable basis of the Company&#146;s ability to regain compliance within the timeframe provided. &nbsp;Accordingly, via correspondence dated January 8, 2009, Staff notified Nephros that it had determined to initiate delisting proceedings against the Company (the &#147;Staff Determination&#148;). &nbsp;Nephros was further notified by Staff that based on the fact that over the previous six month period the price per share of the Company had ranged between $0.06 and 0.60 and had a closing price of $0.12 as of January 7, 2009, Staff deemed it appropriate for the Company to complete a reverse stock split. &nbsp;As such, Nephros was notified that if it chose to appeal the Staff Determination, the Company would be<FONT FACE="CG Times"> expected to address its low selling price and any plans to resolve this issue at a scheduled hearing. &nbsp;</FONT>The
 letter also informed the Company of its limited right, in accordance with Sections 1203 and 1009(d) of the Company Guide, to request a hearing before a Listing Qualifications Panel within seven days of the Staff Determination, or by January 15, 2009.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; padding-left:54pt; text-indent:-18pt; font-size:11pt" align=justify>(d)</P>
<P style="line-height:13pt; margin:0pt; padding-left:54pt; font-size:11pt" align=justify>The Company did not appeal the Staff Determination within the requisite time period or thereafter and was not otherwise in compliance with the Exchange&#146;s continued listing standards. </P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=justify>Accordingly, the Exchange, having complied with all of its procedures, is authorized to file this application in accordance with Section 12 of the Securities Exchange Act of 1934 and the rules promulgated thereunder.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>4.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>In the opinion of the Exchange, all of the material facts relating to the reasons for this application are contained herein.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>5.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>The Exchange official whose signature is set forth below is duly authorized to file this application.</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt" align=justify>6.</P>
<P style="line-height:13pt; margin:0pt; text-indent:36pt; font-size:11pt" align=justify>In accordance with the provisions of Rule 12d2-2, the Exchange has issued public notice of its final determination to remove the Company&#146;s Common Stock from listing and/or registration by issuing a press release and posting notice on <FONT COLOR=#0000FF><U>www.nyse.com/regulation</U></FONT>. &nbsp;Further, a copy of this application has been forwarded to Mr. Ernest A. Elgin III, President and Chief Executive Officer of Nephros, Inc.</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt">/s/</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt">Janice O&#146;Neill </P>
<P style="line-height:13pt; margin:0pt; font-size:11pt">Senior Vice President &#150; Corporate Compliance<BR>
NYSE Regulation, Inc.</P>
<H1>Footnotes</H1>
<P style="margin:0pt; font-family:CG Times" align=justify><FONT FACE="CG Times" COLOR=#000000><SUP>1</SUP></FONT> Subsequently, based on the results of Nephros&#146; quarterly report on Form 10-Q for the period ended September 30, 2008, the Company triggered an additional deficiency, pursuant to Section 1003(a)(ii) of the Company Guide. &nbsp;In this regard, Nephros reported stockholders&#146; equity below $4 million and had sustained losses from continuing operations and net losses in each of its four most recent fiscal years. &nbsp;</P>
<P style="margin:0pt; font-family:CG Times" align=justify><SUP>2</SUP> In setting this truncated deadline for compliance, Staff applied Section 1009(h) of the Company Guide which provides that the Exchange may truncate the continued listing evaluation and follow up procedures if a company, within 12 months of the end of a plan period, is again determined to be below the continued listing standards. &nbsp;</P>
<P style="margin:0pt"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
